Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response

被引：0
作者：
Nora Drick
Benjamin Seeliger
Tobias Welte
Jan Fuge
Hendrik Suhling
机构：
[1] Hannover Medical School,Department of Respiratory Medicine
[2] Biomedical Research in End-Stage and Obstructive Lung Disease Hannover (BREATH),undefined
[3] Member of the German Centre for Lung Research (DZL),undefined
来源：
BMC Pulmonary Medicine | / 18卷
关键词：
Severe eosinophilic asthma; Mepolizumab; Treatment response; IL-5; Lung function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 175 条
[1]  
Stanojevic S(2012)Global asthma prevalence in adults: findings from the cross-sectional world health survey BMC Public Health 12 204-373
[2]  
Moores G(2014)International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma Eur Respir J 43 343-902
[3]  
Gershon AS(2015)The prevalence of severe refractory asthma J Allergy Clin Immunol 135 896-12S
[4]  
Bateman ED(2006)The global burden of asthma Chest 130 4S-639
[5]  
Cruz AA(2015)A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales Qual Life Res 24 631-976
[6]  
Boulet L-P(2017)Severe and difficult-to-treat asthma in adults N Engl J Med 377 965-1197
[7]  
Chung KF(2014)Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma N Engl J Med 371 1189-659
[8]  
Wenzel SE(2012)Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Lancet 380 651-1207
[9]  
Brozek JL(2014)Mepolizumab treatment in patients with severe eosinophilic asthma N Engl J Med 371 1198-366
[10]  
Bush A(2015)Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials Lancet Respir Med 3 355-2458
12345678910